Lexicon Pharmaceuticals (LXRX) Income from Non-Controlling Interests (2022 - 2026)
Lexicon Pharmaceuticals' (LXRX) quarterly Income from Non-Controlling Interests came in at -$160000.0 in Q1 2026, down 70.21% year-on-year from -$537142.9 in Q1 2025, and down 16100.0% on a QoQ basis from $1000.0 in Q4 2025.
Lexicon Pharmaceuticals (LXRX) Income from Non-Controlling Interests (2022 - 2026) Analysis & Trends
Lexicon Pharmaceuticals (LXRX) has 5 years of Income from Non-Controlling Interests data on file, last reported at -$160000.0 in Q1 2026.
- On a quarterly basis, Income from Non-Controlling Interests fell 70.21% year-over-year to -$160000.0 in Q1 2026; TTM through Mar 2026 was -$155000.0, a 306.67% decrease from a year earlier, with the FY2025 full-year figure at -$89000.0, down 201.14% from the prior year.
- Income from Non-Controlling Interests for Q1 2026 stood at -$160000.0, down from $1000.0 in the prior quarter.
- Over the last five years, Income from Non-Controlling Interests for LXRX reached as high as $542000.0 in Q3 2024 and fell as low as -$341000.0 in Q3 2022.
- Historically, Income from Non-Controlling Interests has averaged -$7058.8 across 5 years, with a median of -$27000.0 in 2022.
- On a YoY basis, Income from Non-Controlling Interests climbed as much as 4269.23% in 2024 and fell as far as 326.98% in 2024.
- Year by year, Income from Non-Controlling Interests stood at $63000.0 in 2022, then surged by 128.57% to $144000.0 in 2023, then plunged by 259.72% to -$230000.0 in 2024, then jumped by 100.43% to $1000.0 in 2025, then tumbled by 16100.0% to -$160000.0 in 2026.
- Per Business Quant data, the three most recent Income from Non-Controlling Interests figures were -$160000.0 in Q1 2026, $1000.0 in Q4 2025, and $43000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Lexicon Pharmaceuticals | 888.49 Mn | 717.83 Mn | 20.99 Mn | -160,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -160,000.00 |
| Dec 31, 2025 | 1,000.00 |
| Sep 30, 2025 | 43,000.00 |
| Jun 30, 2025 | -39,000.00 |
| Mar 31, 2025 | -94,000.00 |
| Dec 31, 2024 | -230,000.00 |
| Sep 30, 2024 | 542,000.00 |
| Jun 30, 2024 | -143,000.00 |
| Mar 31, 2024 | -81,000.00 |
| Dec 31, 2023 | 144,000.00 |
| Sep 30, 2023 | -13,000.00 |
| Jun 30, 2023 | 63,000.00 |
| Mar 31, 2023 | 265,000.00 |
| Dec 31, 2022 | 63,000.00 |
| Sep 30, 2022 | -341,000.00 |
| Jun 30, 2022 | -113,000.00 |
| Mar 31, 2022 | -27,000.00 |